Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 5.

Journal Article

Mazieres, J., Novello, S., De Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Wolf, J., Zeaiter, A., Cardona, A., Balas, B., Karagiannis, T., Chlistalla, M., Smoljanovic, V. and Oh, I. (2017). Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC. J. Thorac. Oncol., 12 (11). S. S1897 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Novello, S., Mazieres, J., Oh, I-J., de Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H. K., Das-Gupta, A. and Wolf, J. (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann. Oncol., 29 (6). S. 1409 - 1417. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Novello, S., Mazieres, J., Oh, I-J., de Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeiter, A., Cardona, A., Balas, B., Johannsdottir, H., Das-Gupta, A. and Wolf, J. (2017). Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK plus non-small-cell lung cancer (NSCLC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Wolf, J., Oh, I-J., Mazieres, J., de Castro, J., Revil, C., Kotb, A., Johansdottir, H., Zeaiter, A. and Novello, S. (2016). ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

de Castro, J., Novello, S., Mazieres, J., Oh, I-J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., de Marinis, F., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H., Chlistalla, M., Smoljanovic, V. and Wolf, J. (2017). CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Sat Mar 6 02:11:27 2021 CET.